Treatment Guided by Comprehensive Genomic Profiling and Expert MTB Decision-Making Improves Outcomes in Pretreated Patients with Metastatic Cancer By Ogkologos - October 14, 2025 310 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROME study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Promoting Inclusion for LGBTQ+ People With Cancer: “Your Stories” Podcast September 21, 2021 The Lung Immune Prognostic Index May Indicate Response to Immune Checkpoint... December 9, 2020 Why I Work to Bridge the Gap Between People With Cancer... May 27, 2021 How to Avoid Spreading Harmful Chemo Chemicals to Members of Your... August 4, 2021 Load more HOT NEWS Longer PFS in Patients with Advanced Melanoma Treated with TILs than... When You Lose a Spouse to Cancer and Need Support How we can reduce cancer risk in inflammatory bowel disease patients... Discovering the BRCA2 gene – 25 years on
